Skip to main content

Clinical Trial Search Results

A scientist pointing to an image of a DNA chain.

Clinical Trial Search Results

Showing 289-297 out of 318 results.
NCT04669899

Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Icon for trial | JTX-8064-101 Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with

A medical research study for participants who have been diagnosed with a solid tumor (i.e. cancer) and currently, the tumor is unresponsive to approved treatments, approved treatments are worsening the symptoms or the participa ...

NCT03926624

Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine Decitabine, Venetoclax combination regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage.

Icon for trial | D18-11141 Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine Decitabine, Venetoclax combination regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patie

This study will investigate whether a new experimental treatment, DFP-10917, will be an effective and safe treatment option for patients with relapsed/refractory acute myelogenous leukemia (AML). The purpose of this study is to ...